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ABSTRACT
Background The association between obesity and 
outcomes in patients receiving programmed death-1/
programmed death ligand-1 (PD- L1) checkpoint inhibitors 
has already been confirmed in pre- treated non- small cell 
lung cancer (NSCLC) patients, regardless of PD- L1 tumor 
expression.
Methods We present the outcomes analysis according 
to baseline body mass index (BMI) and BMI variation in a 
large cohort of metastatic NSCLC patients with a PD- L1 
expression ≥50%, receiving first line pembrolizumab. 
We also evaluated a control cohort of metastatic 
NSCLC patients treated with first line platinum- based 
chemotherapy. Normal weight was set as control group.
Results 962 patients and 426 patients were included 
in the pembrolizumab and chemotherapy cohorts, 
respectively. Obese patients had a significantly higher 
objective response rate (ORR) (OR=1.61 (95% CI: 1.04–
2.50)) in the pembrolizumab cohort, while overweight 
patients had a significantly lower ORR (OR=0.59 (95% 
CI: 0.37–0.92)) within the chemotherapy cohort. Obese 
patients had a significantly longer progression- free 
survival (PFS) (HR=0.61 (95% CI: 0.45–0.82)) in the 
pembrolizumab cohort. Conversely, they had a significantly 
shorter PFS in the chemotherapy cohort (HR=1.27 (95% 
CI: 1.01–1.60)). Obese patients had a significantly longer 
overall survival (OS) within the pembrolizumab cohort 
(HR=0.70 (95% CI: 0.49–0.99)), while no significant 
differences according to baseline BMI were found in the 
chemotherapy cohort. BMI variation significantly affected 
ORR, PFS and OS in both the pembrolizumab and the 
chemotherapy cohorts.
Conclusions Baseline obesity is associated to 
significantly improved ORR, PFS and OS in metastatic 
NSCLC patients with a PD- L1 expression of ≥50%, 
receiving first line pembrolizumab, but not among 
patients treated with chemotherapy. BMI variation is also 
significantly related to clinical outcomes.
INTRODUCTION
Obesity- associated inflammation has been 
shown to dysregulate the immune response, 
potentially having profound effects on the 
toxicity and efficacy of immunotherapy across 
different type of malignancies.1–5 In non- small 
cell lung cancer (NSCLC), recent evidences 
have already confirmed the positive associa-
tion between obesity and improved outcomes 
in patients receiving immune checkpoint 
inhibitors as further line of therapy, regard-
less of programmed death ligand-1 (PD- L1) 
tumor expression.6 7 Moreover, a pooled 
post- hoc analysis of data from four prospec-
tive trials (two of which randomized, with 
docetaxel as control arm) of pre- treated 
NSCLC patients receiving atezolizumab 
has provided robust evidences supporting 
this hypothesis.8 Importantly, Kichenadasse 
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and colleagues confirmed that obesity was associated to 
survival benefit (compared with normal- weight patients) 
in patients treated with atezolizumab, but not in those who 
received chemotherapy, suggesting a predictive as well as 
a prognostic role of a high body mass index (BMI).8 Of 
note, the survival benefit was more pronounced in the 
PD- L1- positive subgroup, while a loss of statistical signif-
icance was reported within the PD- L1- negative patients.8
Accordingly, some evidences suggest that adipose tissue 
might play a pivotal role in regulating the immune homeo-
stasis.9 10 In a recent meta- analysis including 203 articles, 
more than 6,000,000 patients across 15 different malig-
nancies, the association between obesity and improved 
clinical outcomes was confirmed in those tumor types 
in which programmed death-1 (PD-1)/PD- L1 check-
point inhibitors have proven to be more effective (such 
as lung cancer and renal cell carcinoma), despite studies 
involving patients who received immune checkpoint 
inhibitors were poorly represented in the meta- analysis 
itself.11 Therefore, assuming that the adipose tissue has 
somehow a role in the antitumor immune response, 
evaluating whether the variation of the BMI in patients 
receiving immune checkpoint inhibitors affects the clin-
ical outcomes represents an interesting area of research.
Recently, we published a large real- world multicenter 
study of metastatic NSCLC patients with a PD- L1 expres-
sion ≥50%, receiving first line single agent pembroli-
zumab at 34 European institution, aimed at investigating 
the clinic- pathologic correlates of efficacy.12 Here, we 
present the clinical outcomes analysis according to base-
line BMI and BMI variation (defined as ΔBMI) of the 
same study population. In order to confirm the results, 
we also evaluated a control cohort of metastatic NSCLC 
patients treated with first line platinum- based chemo-
therapy in clinical practice.
MATERIALS AND METHODS
Study design
We assessed baseline BMI and ΔBMI within the study 
population of a real- world multicenter retrospective study 
evaluating metastatic NSCLC patients with PD- L1 expres-
sion ≥50%, consecutively treated with first line pembroli-
zumab monotherapy, from January 2017 to October 2019, 
at 34 institutions (online supplemental table 1).12 13 In 
order to weighing our results, we also evaluated the base-
line BMI and ΔBMI in a cohort of metastatic epidermal 
growth factor receptor wild- type NSCLC patients treated 
with platinum- based doublet chemotherapy in clinical 
practice from January 2013 to January 2020, at 10 among 
the above- mentioned institutions. Patients were treated in 
clinical practice with either the 2 mg/kg q3 weeks sched-
ules (before the procedure N° EMEA/H/C/3820/II/48) 
and the 200 mg q3 weeks flat dose.
The aim of this analysis was to evaluate clinical 
outcomes according to baseline BMI and ΔBMI in both 
the pembrolizumab and chemotherapy cohorts. The 
measured clinical outcomes were objective response 
rate (ORR), median progression- free survival (PFS) and 
median overall survival (OS). Patients were assessed with 
radiological imaging in clinical practice, with a frequency 
ranging from 12 to 16 weeks, according to the moni-
toring requirements for high- cost drugs of the respective 
national drug regulatory agencies (eg, the on- line moni-
toring dashboard of the ‘Agenzia Italiana del Farmaco’ 
requires a disease assessment at least every 16 weeks; avail-
able at: https:// servizionline. aifa. gov. it/). Radiologists 
evaluation was based on Response Evaluation Criteria 
In Solid Tumors (RECIST criteria (V.1.1),14 and a subse-
quent confirming imaging was recommended. However, 
treatment beyond disease progression was allowed and 
also patients evaluated according to the clinicians assess-
ment in clinical practice were considered eligible. The 
reliability of disease response evaluation in clinical prac-
tice was assessed through Kaplan- Meier survival curves for 
PFS and OS according to the best response (categorized 
as partial/complete response, stable disease and progres-
sive disease) (online supplemental figure 1).
ORR was defined as the portion of patients experiencing 
an objective response (complete or partial response) as 
best response to immunotherapy. PFS was defined as the 
time from treatment initiation to disease progression 
or death, whichever occurred first. OS was defined as 
the time from treatment initiation to death. For PFS as 
well as for OS, patients without events were considered 
as censored at the time of the last follow- up. Data cut- off 
period was February 2020 for the pembrolizumab cohort 
and April 2020 for the chemotherapy cohort.
Considering the possible unbalanced distribution, the 
influence of large within group variation and the possible 
interactions, fixed multivariable regression models were 
used to estimate clinical outcomes (ORR, PFS and OS) 
according to baseline BMI and ΔBMI by using pre- planned 
adjusting key covariates in both the pembrolizumab and 
chemotherapy cohorts.15–17 The key covariates were: age 
(<70 vs ≥70 years old),18 gender (male vs female), Eastern 
Cooperative Oncology Group—Performance Status 
(ECOG- PS) (0–1 vs ≥2), central nervous system (CNS) 
metastases (yes vs no), bone metastases (yes vs no) and 
liver metastases (yes vs no).
BMI evaluation
Weight and height were obtained from patient medical 
records; BMI was calculated using the formula of weight/
height2 (kilograms per square meter) and catego-
rized according to the WHO categories: underweight, 
BMI<18.5; normal- weight, 18.5≤BMI≤24.9; overweight, 
25≤BMI≤29.9; obese, BMI≥30. In all the regression 
analyses, normal- weight patients were considered as 
the comparator group. ΔBMI was defined as the BMI 
percentage variation from treatment initiation to disease 
progression (or to the last contact for censored patients). 
In order to guarantee a minimum time lapse for ΔBMI 
assessment and to overcome selection biases related to 
some fast disease progressions, which might have flawed 
our determinations, the efficacy analysis according to the 
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ΔBMI was performed after a 4 weeks landmark selection, 
including only patients with a minimum follow- up for PFS 
of 4 weeks. To identify an optimal grouping according to 
the ΔBMI and determine appropriate cut- offs with respect 
to ORR, PFS and OS in the pembrolizumab, a recursive 
partitioning algorithm was performed, using the Rpart 
function in R. The computed cut- offs were than applied to 
the chemotherapy cohort, following the rules of external 
validation.19 However, in order to properly weighing the 
role of the ΔBMI, a recursive partitioning was performed 






426 n (%) χ2 test
Pembrolizumab 




cohort (4 weeks 
landmark)
414 n (%) χ2 test
Age (years)
  Median 70.1 66.0 70.2 66.0
  Range 28–92 24–85 p<0.0001 28–92 24–84 p=0.0002
  Elderly (≥70) 491 (51.0) 167 (39.2) 410 (51.3) 165 (39.9)
Smoking status
  Former/current 864 (89.8) 378 (88.7) p=0.5452 719 (90.0) 369 (89.1) p=0.6417
  Never 98 (10.2) 48 (11.3) 80 (10.0) 45 (10.9)
Sex
  Male 635 (66.0) 295 (69.2) p=0.2365 535 (67.0) 288 (69.6) p=0.3569
  Female 327 (34.0) 131 (30.8) 264 (33.0) 126 (30.4)
ECOG PS
  0–1 793 (82.4) 396 (93.0) p<0.0001 685 (85.7) 385 (93.0) p=0.0002
  ≥2 169 (17.6) 30 (7.0) 114 (14.3) 29 (7.0)
Histology
  Squamous 232 (24.1) 95 (22.3) p=0.4623 188 (23.5) 95 (22.9) p=0.8201
  Non- squamous 730 (75.9) 331 (77.7) 611 (76.5) 319 (77.1)
CNS metastases
  Yes 171 (17.8) 67 (15.7) p=0.3507 138 (17.3) 66 (15.9) p=0.5574
  No 791 (82.2) 359 (84.3) 661 (82.7) 348 (84.1)
Bone metastases
  Yes 310 (32.2) 115 (27.0) p=0.0513 240 (30.0) 112 (27.1) p=0.2777
  No 652 (67.8) 311 (73.0) 559 (70.0) 302 (72.9)
Liver metastases
  Yes 150 (15.7) 57 (13.4) p=0.2730 119 (14.9) 56 (13.5) p=0.5207
  No 808 (84.3) 369 (86.6) 680 (85.1) 358 (86.5)
BMI (kg/m2)
  Median (range) 24.2 (14.0–44.9) 24.9 (15.7–41.8) 24.2 (14.0–44.9) 24.9 (15.7–41.8)
  Underweight 
(≤18.5)
40 (4.2) 16 (3.8) p=0.0505 40 (4.2) 10 (2.4) p=0.0210
  Normal weight 
(18.5–25)
526 (54.9) 202 (47.4) p=0.0287* 526 (54.9) 200 (48.3) p=0.0089*
  Overweight 
(25–30)
275 (28.7) 150 (35.2) 275 (28.7) 147 (35.5)
  Obese (≥30) 117 (12.2) 58 (13.6) 117 (12.2) 57 (13.8)
ΔBMI (sample) – – (799) (83.1) (414) (97.2)
  Median – – 0% 0%
  Range (−34% to +34%) (−22% to +27%)
*χ2 test for trend.
BMI, body mass index; CNS, central nervous system; ECOG- PS, Easter Cooperative Oncology Group—Performance Status.
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to compute the cut- offs with respect to ORR, PFS and OS 
also within the chemotherapy cohort.
Statistical analysis
Baseline patient characteristics were reported with 
descriptive statistics and compared between the pembroli-
zumab cohort and chemotherapy cohort with the χ2 test. 
χ2 test was also used to compare ORRs according to BMI 
and ΔBMI in both the cohorts. Logistic regression was 
used for the multivariate analysis of ORR. Median PFS 
and median OS were evaluated using the Kaplan- Meier 
method. Median period of follow- up was calculated 
according to the reverse Kaplan- Meier method. Cox 
proportional hazards regression was used for the fixed 
multivariate analysis of PFS and OS. The alpha level for all 
analyses was set to p<0.05. Adjusted hazard ratios (aHRs) 
and adjusted odds ratios (aORs) with 95% CIs were calcu-
lated. Forest plot graphs were used to compare HRs and 
ORs between the pembrolizumab and the chemotherapy 
cohorts. All statistical analyses were performed using 
MedCalc Statistical Software V.18.11.3 (MedCalc Soft-
ware bvba, Ostend, Belgium; http://www. medcalc. org; 
2019). Recursive partitioning was performed using the R 
package rpart (R V.3.6.2).
RESULTS
Patients characteristics
Table 1 summarizes patients characteristics of both the 
cohorts. Nine hundred and sixty- two patients and 426 
patients were included in the pembrolizumab and chemo-
therapy cohorts, respectively. Median age was 70.1 and 
66.0 years; the rate of elderly patients was significantly 
higher in the pembrolizumab cohort, compared with 
the chemotherapy cohort (51.0% vs 39.2%, p<0.0001), as 
well as the rate of patients with an ECOG- PS of ≥2 (17.6% 
vs 7.0%, p<0.0001). The median baseline BMI was 24.2 
for the pembrolizumab cohort and 24.9 for the chemo-
therapy cohort; normal- weight patients were the majority 
of both the cohort (54.9% and 47.4%, respectively), but 
the χ2 test for trend revealed that there was a statistically 
significant trend of higher BMI categories to be more 
frequent through the chemotherapy cohort (p=0.0287). 
After the 4 weeks landmark selection, 799 (83.1%) and 
414 (97.2%) of the patients from the pembrolizumab 
and chemotherapy cohorts were included in the ΔBMI 
analysis, respectively (online supplemental figure 2). The 
median ΔBMI was 0% for both the cohorts. Notably, the 
median follow- up periods were 14.6 months (95% CI: 
13.5–15.6) and 37.2 months (95% CI: 31.7–44.1) for the 
Table 2 Optimal grouping according to ΔBMI computed through the recursive partitioning algorithm with respects to the 
objective response rate (ORR), progression- free survival (PFS) and overall survival (OS)
Pembrolizumab cohort Chemotherapy cohort
ORR PFS OS ORR PFS OS
ΔBMI (%) computed cut- off +1.4 +1.4 +1.4 +7.1 −6.8 −2.2
  ≥cut off 173 (24.0%) 183 (22.9%) 183 (22.9%) 36 (8.8%) 345 (83.3%) 266 (64.3%)
  <cut- off 548 (76.0%) 616 (77.1%) 616 (77.1%) 375 (91.2%) 69 (16.7%) 148 (35.7%)
BMI, body mass index.
Table 3 Summary of the objective response rate (ORR) in the pembrolizumab cohort and chemotherapy cohort according to 







ratio ORR (%) (95% CI)
Response- 
ratio ORR (%) (95% CI)
BMI (kg/m2)
  Underweight (≤18.5) 10/35 28.6 (13.7–52.5) p=0.0077
p=0.0910*
5/15 33.3 (10.8–77.8) p=0.0758
p=0.3079*  Normal weight (18.5–25) 201/467 43.0 (37.3–49.4) 96/199 48.2 (39.1–58.9)
  Overweight (25–30) 97/232 41.8 (33.9–51.0) 54/149 36.2 (27.2–47.3)
  Obese (≥30) 61/106 57.5 (44.0–73.9) 29/57 50.9 (34.1–73.1)
ΔBMI   
  ≥1.4% 116/173 67.1 (55.4–80.4) p<0.0001 72/119 60.5 (47.3–76.2) p<0.0001*
  <1.4% 227/548 41.4 (36.2–47.2) 111/292 38.0 (31.2–45.8)
*χ2 test for trend.
BMI, Body mass index.
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pembrolizumab and chemotherapy cohorts, respectively. 
One hundred ninety- three patients (20%) within the 
pembrolizumab cohort had received a further systemic 
treatment, while 249 patients (58.5%) within the chemo-
therapy cohort had received a further treatment with 
either PD-1 or PD- L1 checkpoint inhibitors at the data 
cut- off. Table 2 summarizes the recursive partitioning 
results. Interestingly, the computed cut- offs for ORR, 
PFS and OS were the same positive value (BMI gain of 
1.4%) within the pembrolizumab cohort, which was set as 
fixed cut- off for the clinical outcomes analysis of both the 
cohorts. On the other hand, in the chemotherapy cohort 
the computed cut- off for ORR was a positive value (BMI 
gain of 7.1%), while was a negative value for PFS and OS 
(BMI loss of 6.8% and 2.2%, respectively).
Clinical outcomes analysis
The ORR for the pembrolizumab cohort overall was 
44.1% (95% CI: 39.7–48.8) (372/844 response ratio), 
while was 43.8% for the chemotherapy cohort overall 
(95% CI: 37.7–50.6) (184/420 response ratio). The 
median PFS and OS for the pembrolizumab cohort were 
8.0 months (95% CI: 6.9–9.6; 559 progression events) and 
18.6 months (95% CI: 16.1–27.5; 567 censored patients), 
respectively, while the median PFS and OS for the chemo-
therapy cohort were 6.1 months (95% CI: 5.7–6.5; 387 
progression events) and 16.5 months (95% CI: 13.6–18.7; 
136 censored), respectively (online supplemental figure 
3). Table 3 summarizes the ORRs of both the pembroli-
zumab and chemotherapy cohorts, according to the 
baseline BMI and ΔBMI of 1.4%. Patients with a high 
baseline BMI had a significantly higher ORR within the 
pembrolizumab cohort (p=0.0077), but not within the 
chemotherapy cohort (p=0.0758). The ΔBMI evaluated 
according to the computed cut- off significantly affected 
the ORR and patients with a BMI gain of ≥1.4% had a 
higher BMI in both the pembrolizumab (p<0.0001) and 
the chemotherapy (p<0.0001) cohorts. Table 4 summa-
rizes the multivariate regression analyses for ORR with 
the pre- planned fixed adjusting factors. Obese patients 
were confirmed to have a significantly higher ORR 
compared with normal- weight patients (aOR=1.61 (95% 
CI: 1.04–2.50), p=0.0348) within the pembrolizumab 
cohort, while overweight patients had a significantly lower 
ORR compared with normal- weight patients (aOR=0.59 
(95% CI: 0.37–0.92), p=0.0208) within the chemotherapy 
cohort. Also, at the multivariate analysis. the ΔBMI of 
1.4% significantly affected the ORR within the pembroli-
zumab cohort (aOR=2.78 (95% CI: 1.92–4.16), p<0.0001) 
and the chemotherapy cohort (aOR=2.38 (95% CI: 1.51–
3.70), p=0.0002). Figure 1 reports the forest plot graph 
for the ORR of the pembrolizumab and chemotherapy 
cohorts according to baseline BMI and ΔBMI.
Table 5 summarizes the multivariate regression for 
PFS. Obese patients were confirmed to have a signifi-
cantly longer PFS compared with normal- weight 
patients (aHR=0.61 (95% CI: 0.45–0.82), p=0.0012) 
in the pembrolizumab cohort. Conversely, they had a 
significantly shorter PFS compared with normal- weight 
patients in the chemotherapy cohort (aHR=1.37 (95% 
CI: 1.01–1.87), p=0.0477). ΔBMI of 1.4% significantly 
affected the PFS of both the pembrolizumab cohort 
(aHR=0.39 (95% CI: 0.29–0.51), p<0.0001) and the 
chemotherapy cohort (aHR=0.78 (95% CI: 0.62–0.99), 
p=0.0341). Figure 2 reports the forest plot for the PFS 
of the two cohort according to baseline BMI and ΔBMI.
Table 6 summarizes the multivariate regression for OS. 
Obese patients had a significantly longer OS compared 
with normal- weight patients within the pembrolizumab 
Figure 1 Forest plot graph for objective response rate (ORR). aOR, adjusted OR; BMI, body mass index.
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cohort (aHR=0.70 (95% CI: 0.49–0.99)), while no signif-
icant differences according to baseline BMI were found 
in the chemotherapy cohort. ΔBMI of 1.4% significantly 
affected the OS within both the pembrolizumab cohort 
(aHR=0.33 (95% CI: 0.22–0.48), p<0.0001) and the chemo-
therapy cohort (aHR=0.73 (95% CI: 0.56–0.96), p=0.0241). 
Figure 3 reports the forest plot graph for the OS of the two 
cohorts according to baseline BMI and ΔBMI.
Online supplemental figure 4 reports the Kaplan- Meier 
survival curves of PFS and OS according to baseline BMI; 
online supplemental figure 5 reports the Kaplan- Meier 
survival curves of PFS and OS according to the ΔBMI for 
both the cohorts.
DISCUSSION
In this study we confirmed that also in a population of 
NSCLC patients with a PD- L1 expression ≥50% receiving 
first line pembrolizumab, obesity is associated to 
improved clinical outcomes. Obese patients had a signifi-
cantly higher ORR, and prolonged PFS and OS compared 
with normal- weight patients. The fact that this trend was 
confirmed at each outcome analysis (ORR, PFS and OS) 
and with multivariate regression models further supports 
our results. More importantly, we did not observe such 
correlation among patients treated with chemotherapy, 
suggesting that the obesity- related clinical benefit is 
unique of patients treated with immunotherapy. Of note, 
obese patients who received chemotherapy had a non- 
significant trend towards a lower ORR and shorter OS, and 
a significantly shorter PFS, compared with normal- weight 
patients. These evidences are aligned to what already 
reported for NSCLC patients in clinical practice,6 7 20 and 
to the improved survival observed in obese PD- L1- positive 
NSCLC patients by Kichenadasse et al.8 Consistently 
with our results, also in the control cohort of the study 
by Kichenadasse and colleagues, no survival benefit was 
Table 5 Summary of the multivariate analysis (MVA) with Cox proportional- hazards of progression- free survival (PFS)
Variable
(comparator)
Pembrolizumab cohort—MVA PFS Chemotherapy cohort—MVA PFS
aHR (95% CI); p value aHR (95% CI); p value aHR (95% CI); p value aHR (95% CI); p value
BMI (normal 
weight)
      












ΔBMI       
  ≥1.4% vs <1.4% – 0.39 (0.29–0.51); 
p<0.0001
– 0.78 (0.62–0.99); 
p=0.0341
Gender       








Age       










CNS metastases       








Bone metastases       








Liver metastases       








ECOG- PS       








aHR, adjusted HR; BMI, body mass index; CNS, central nervous system; ECOG- PS, Easter Cooperative Oncology Group—Performance 
Status.
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reported for obese patients who received chemotherapy.8 
Remarkably, obese patients in the chemotherapy cohort 
did not have an improved OS despite 58.5% of them 
received immunotherapy on chemotherapy failure.
As previously mentioned, a growing body of evidence 
is indicating that the adipose tissue might play a critical 
role in shaping the antitumor immune responses. Wang 
and colleagues reported that obese mice showed a signif-
icant increase of dysfunctional exhausted T- cell.9 Such 
exhaustion could be partially mediated by the immune 
checkpoints (as the PD-1/PD- L1 pathway) and driven by 
leptin, and then might be more likely elicited by immune 
checkpoints inhibitors.9 10
Nonetheless, a high baseline BMI has been histor-
ically somehow associated to improved lung cancer 
survival across different disease stages, even in the ‘pre- 
immune checkpoint inhibitors era’, reflecting the poten-
tial prognostic nature of baseline BMI in lung cancer 
patients.21–24 However, we need to highlight that even if 
cancer cachexia mechanisms are not completely known 
yet, several evidences showed that the systemic inflamma-
tion plays a central role.25 Lung cancer is an aggressive 
disease, and metastatic NSCLC patients usually to present 
with poor clinical condition and weight loss at the time 
of first line treatment commencement, which underlies a 
systemic inflammatory over- activation.26 From this point 
of view, a higher baseline BMI might be considered a sign 
of functional reserve and a protective feature for NSCLC 
advanced patients.
To that end, in a study evaluating 2585 stage IV NSCLC 
patients from three trials with first line chemotherapy, 
obesity was associated with improved OS.27 Intriguingly, 
when time on- study exceeded 16 months, obese patients 
experienced a significant increase in their hazard rate 
for death, compared with normal/overweight patients, 
suggesting a possible negative role of the sarcopenic 
obesity in the long- term during chemotherapy.27
Also, the efficacy analysis according to ΔBMI revealed 
interesting results. A BMI variation of 1.4% during treat-
ment was significantly (and concordantly) related to each 
measured outcome (ORR, PFS and OS) for both the 
pembrolizumab and chemotherapy cohorts. Looking to 
the forest plot graphs, we can notice that the aOR and 
the aHRs were concordantly more pronounced for the 
pembrolizumab cohort. Similarly, the Kaplan- Meier 
survival curves according to the ΔBMI (online supple-
mental figure 4) show a much more marked survival 
benefit for patients who experienced a BMI gain of 
≥1.4% within the pembrolizumab cohort rather than in 
the chemotherapy cohort. These findings could make 
us assuming that the prognostic role ΔBMI is stronger 
during the immunotherapy rather than chemotherapy. 
However, we must not fail in taking into account that 
the optimal grouping computed with the recursive parti-
tioning algorithm within the patients receiving pembroli-
zumab was applied to both the cohorts. Interestingly with 
respect to the optimal grouping, while for the pembroli-
zumab cohort a harmonic positive cut- off for ΔBMI was 
found for ORR, PFS and OS (+1.4%), three different cut- 
offs were found among the chemotherapy cohort using a 
recursive partitioning: a positive value for ORR (+7.1%), 
and two different negative values for PFS (−6.8%) and OS 
(−2.2%). Although using different cut- offs for the same 
variable may seem redundant, the results raise some ques-
tions. A harmonic and relatively small weight gain during 
pembrolizumab could be considered a concordant inde-
pendent predictor for ORR, PFS and OS. Conversely, a 
more pronounced weight gain during chemotherapy is 
associated with ORR, while a weight loss is significantly 
associated with inferior PFS and OS. From this perspective, 
the BMI acts differently in the two cohorts; considering 
the adipose tissue an immune organ, patients who expe-
rienced a slight weight gain during immunotherapy had 
a significantly improved ORR, PFS and OS. Considering 
Figure 2 Forest plot graph for progression- free survival (PFS). aHR, adjusted HR; BMI, body mass index.
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instead the adipose tissue as a functional reserve for 
patients receiving chemotherapy, a pronounced weight 
gain is related to an improved ORR, while a weight loss 
had a significant prognostic negative role for PFS and 
OS. In a post- hoc analysis from three phase III studies 
of patients receiving a platinum- based systemic therapy, 
Patel and colleagues evaluated the clinical outcomes 
according to a pre- planned weight gain cut- off (> vs ≤5%), 
assessed by monitoring post- baseline weight variation till 
the maximum weight during treatment or at the 30- day 
post- study discontinuation follow- up visit.28 The authors 
reported that a weight gain of >5% were significantly 
related to improved ORR, PFS and OS.28 However, the 
different methodology does not allow a direct compar-
ison between our chemotherapy cohort and the cohort 
of Patel et al.28
Our study has several limitations beyond the retro-
spective design and the consequent selection biases. 
First, we cannot consider the chemotherapy cohort a 
proper validation cohort, because we did not perform 
any case- control matching; the percentage of elderly 
patients and patients with ECOG- PS ≥2 are in fact signifi-
cantly different. Considering the good clinical outcomes 
achieved in absolute terms, the chemotherapy cohort 
might had been positively biased. These findings are 
likely to be related to the clinicians attitude to treat with 
doublet chemotherapy more fit patients, compared with 
single agent pembrolizumab. Moreover, this positive 
selection might partially subtend to the lack of associ-
ation between survival and BMI in the chemotherapy 
cohort. From this perspective, the analysis of the chemo-
therapy cohort collides with the evidences suggesting 
that also in NSCLC patients receiving chemotherapy 
a higher BMI is associated with an improved survival.11 
Additional limitations include the data lack availability 
regarding comorbidities, the different sample size of the 
Table 6 Summary of the multivariate analysis (MVA) with Cox proportional- hazards of overall survival (OS)
Variable
(comparator)
Pembrolizumab cohort—MVA OS Chemotherapy cohort—MVA OS
aHR (95% CI); p value aHR (95% CI); p value aHR (95% CI); p value aHR (95% CI); p value
BMI (normal 
weight)
      








  Obese 0.70 (0.49–0.99); 
p=0.0474
– 1.29 (0.89–1.86); 
p=0.1763
–
ΔBMI       
  ≥1.4% vs <1.4% – 0.33 (0.22–0.48); 
p<0.0001
– 0.73 (0.56–0.96); 
p=0.0241
Gender       








Age       










CNS metastases       








Bone metastases       








Liver metastases       








ECOG- PS       








aHR, adjusted HR; BMI, body mass index; CNS, central nervous system; ECOG- PS, Easter Cooperative Oncology Group—Performance 
Status.
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two cohorts, as well as the median follow- up which was 
different. The chemotherapy cohort was not powered 
to detect statistically significant differences according 
to weight categories, moreover, being a historic cohort, 
we did not have data regarding PD- L1 expression for 
the subset of patients treated with chemotherapy. Never-
theless, considering the real- world prevalence of PD- L1 
expression in NSCLC, we can assume that we one- third 
of the patients in the chemotherapy cohort had a PD- L1 
expression of ≥50%.29 Without having the weight data at 
pre- specified time points, we computed the ΔBMI from 
treatment commencement to disease progression or 
to the last contact for censored patients, who, however, 
were progression free at the data cut- off and might had 
been positively selected with regards of the weight gain 
(due to better clinical condition). Conversely, progressed 
patients might have been negatively selected regarding 
the weight loss, even if the 4 weeks landmark selection 
was performed to mitigate this bias. In this respect, in our 
population, the probability of experience a BMI varia-
tion was conditional on the PFS, which was longer for the 
pembrolizumab cohort. Despite this, the median ΔBMI 
was the same in the two cohort.
We have also to consider that with the weight- based dose 
overweight/obese patients have been exposed to higher 
dose intensity of pembrolizumab. Nevertheless, phar-
macokinetic studies did not report definitive findings in 
exposure differences nor in safety profiles between the 
regimens (weight- based and fixed dose).30 Furthermore, 
weight variation is inevitably related to the food intake, 
and chemotherapy is certainly associated to a higher inci-
dence of anorexia, nausea and emesis compared with 
single agent pembrolizumab.
CONCLUSION
We confirmed that baseline obesity is associated to signifi-
cantly improved ORR, PFS and OS also in metastatic 
NSCLC patients with a PD- L1 expression of ≥50%, 
receiving first line single agent pembrolizumab, but not 
among patients treated with chemotherapy. BMI varia-
tion during treatment is also significantly related to clin-
ical outcomes, but it seems to have a different role for 
patients receiving first line pembrolizumab, compared 
with patients receiving first line platinum- based 
chemotherapy.
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